| abstract |
A bioerodible implant for use in the treatment of an eye disease, comprising an active agent dispersed in a biodegradable polymer matrix, wherein the biodegradable polymer matrix comprises a mixture of PLGA having hydrophilic terminal groups, wherein said terminal group Hydrophilic is carboxyl, hydroxyl, polyethylene glycol or a combination thereof and PLGA having hydrophobic terminal groups, wherein said hydrophobic terminal group is an alkyl ester or aromatic ester, wherein the bioerodible implant is formed by an extrusion process, and is confirmed for implantation in an ocular region, and where the active agent comprises dexamethasone and 10 to 90 percent by weight of the bioerodible implant. |